Pfizer’s rivipansel fails to meet key endpoints in phase 3 SCD study

This article was originally published here

The phase 3 rivipansel evaluating safety, efficacy and time to discharge (RESET) study evaluated 345 patients who were randomised 1:1 to receive rivipansel or placebo, administered intravenously every

The post Pfizer’s rivipansel fails to meet key endpoints in phase 3 SCD study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply